4.4 Article

Trends in detectable viral load by calendar year in the Australian HIV observational database

Journal

Publisher

JOHN WILEY & SONS LTD
DOI: 10.1186/1758-2652-14-10

Keywords

-

Funding

  1. Foundation for AIDS Research
  2. amfAR
  3. US National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) [U01-AI069907]
  4. Merck Sharp Dohme
  5. Gilead
  6. Bristol-Myers Squibb
  7. Boehringer Ingelheim
  8. Roche
  9. Pfizer
  10. GlaxoSmithKline
  11. Janssen-Cilag

Ask authors/readers for more resources

Background: Recent papers have suggested that expanded combination antiretroviral treatment (cART) through lower viral load may be a strategy to reduce HIV transmission at a population level. We assessed calendar trends in detectable viral load in patients recruited to the Australian HIV Observational Database who were receiving cART. Methods: Patients were included in analyses if they had started cART (defined as three or more antiretrovirals) and had at least one viral load assessment after 1 January 1997. We analyzed detectable viral load (>400 copies/ml) in the first and second six months of each calendar year while receiving cART. Repeated measures logistic regression methods were used to account for within and between patient variability. Rates of detectable viral load were predicted allowing for patients lost to follow up. Results: Analyses were based on 2439 patients and 31,339 viral load assessments between 1 January 1997 and 31 March 2009. Observed detectable viral load in patients receiving cART declined to 5.3% in the first half of 2009. Predicted detectable viral load based on multivariate models, allowing for patient loss to follow up, also declined over time, but at higher levels, to 13.8% in 2009. Conclusions: Predicted detectable viral load in Australian HIV Observational Database patients receiving cART declined over calendar time, albeit at higher levels than observed. However, over this period, HIV diagnoses and estimated HIV incidence increased in Australia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available